Emerging immunopharmacological targets in multiple sclerosis.

  title={Emerging immunopharmacological targets in multiple sclerosis.},
  author={Mojtaba Farjam and Guang-xian Zhang and Bogoljub Ciric and Abdolmohamad M. Rostami},
  journal={Journal of the neurological sciences},
  volume={358 1-2},
Inflammatory demyelination of the central nervous system (CNS) is the hallmark of multiple sclerosis (MS), a chronic debilitating disease that affects more than 2.5 million individuals worldwide. It has been widely accepted, although not proven, that the major pathogenic mechanism of MS involves myelin-reactive T cell activation in the periphery and migration into the CNS, which subsequently triggers an inflammatory cascade that leads to demyelination and axonal damage. Virtually all MS… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-9 of 9 extracted citations


Publications referenced by this paper.
Showing 1-10 of 194 references


  • M. S. Weber, T. Prod'homme, J. C. Patarroyo, N. Molnarfi, T. Karnezis
  • Lehmann- Horn, et al., B-cell activation…
  • 2015


  • C. Constantinescu, A. Asher, W. Fryze, W. Kozubsk, J. Aram
  • Tanasescu, et al., Randomized phase 1b trial of…
  • 2015

The immunoregulator soluble TACI is released by ADAM 10 and re fl ects B cell activation in autoimmunity

  • P. H. Kuhn, S. A. Laurent, S. M. Hauck, K. Berer, S. A. Wendlinger
  • J . Immunol .
  • 2015

Similar Papers

Loading similar papers…